Testosterone transdermal - Acrux
Alternative Names: Luramist; Testosterone MDTS®; Testosterone transdermal spray - AcruxLatest Information Update: 13 Nov 2021
At a glance
- Originator Acrux
- Developer Acrux; Fempharm; Howard Florey Institute; National Health and Medical Research Council Clinical Trials Centre
- Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Hormonal replacements; Small molecules; Testosterone congeners
- Mechanism of Action Testosterone congener stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Female sexual dysfunction
Highest Development Phases
- Discontinued Cognition disorders; Female sexual dysfunction